Germline variants in cancer therapy

Area of Science:

• Pharmacogenetics
• Cancer Genomics
• Drug Metabolism

Background:

• Cancer pharmacogenetics integrates germline (patient) and somatic (tumor) genetic variations.
• Germline variants can predict adverse drug reactions or treatment efficacy, while somatic mutations offer therapeutic targets.
• Key genes involved include those for drug metabolism (e.g., thiopurine S-methyltransferase, UGT1A1, DPD) and drug transport (e.g., ABCB1, ABCG2, ABCC).

Purpose of the Study:

• To evaluate the impact of hereditary variants in key enzymes and transporters on cancer treatment outcomes.
• To discuss the role of gene expression regulation, epigenetics, and posttranscriptional modifications in cancer pharmacogenetics.

Main Methods:

• Review and analysis of published literature on hereditary variants in biotransformation enzymes and drug transporters.
• Examination of the relationship between these variants and responses to cytostatics and targeted cancer therapies.
• Discussion of epigenetic and posttranscriptional regulatory mechanisms influencing gene expression.

Main Results:

• Hereditary variants in enzymes like thiopurine S-methyltransferase, UGT1A1, and DPD are critical for predicting drug response and toxicity.
• Polymorphisms in ABC transporters (ABCB1, ABCG2, ABCC) significantly affect the efficacy and safety of various cancer drugs.
• Epigenetic and posttranscriptional factors add another layer of complexity to cancer pharmacogenetics.

Conclusions:

• Germline genetic testing is essential for personalizing cancer pharmacotherapy and minimizing adverse events.
• Understanding the interplay between germline variants, somatic mutations, and gene regulation is crucial for optimizing cancer treatment strategies.
• Pharmacogenetics, including epigenetic and posttranscriptional modifications, offers a pathway towards more effective and safer cancer therapies.